https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00355-2/fulltext
0
0
1/6/23 at 11:36pm
Organization
The Lancet
Authors
Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia
and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection.
Post-acute care for those with COVID-19 should involve attention to dyslipidaemia
as a…
Create an account
or login to join the discussion